Literature DB >> 10738526

Supportive evidence for contribution of the dopamine D2 receptor gene to heritability of stature: linkage and association studies.

T Arinami1, Y Iijima, K Yamakawa-Kobayashi, H Ishiguro, T Ohtsuki, H Yanagi, Y Shimakura, H Ishikawa, H Hamaguchi.   

Abstract

Increases in height were reported in children chronically exposed prenatally and postnatally to D2 receptor-blocking drugs. A possible haplotypic association between stature and the DRD2 gene was also reported. In this study, we examined linkage between stature and DRD2 by genotyping a dinucleotide repeat polymorphism in 79 sib-pairs aged 8-17 years. An association between stature and a putative functional polymorphism in the promoter region of the DRD2 gene was examined in the sib-pairs and in 125 unrelated male adults. All the subjects were Japanese. Linkage (p = 0.004, SIBPAL) and an association (p = 0.009, paired t-test, in the sib-pairs; p = 0.006, ANOVA, in the adults) with stature were suggested. These findings indicate that DRD2 is one of the genes that contribute to heritability of stature.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10738526     DOI: 10.1046/j.1469-1809.1999.6320147.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  3 in total

1.  Human fertility variation, size-related obstetrical performance and the evolution of sexual stature dimorphism.

Authors:  J F Guégan; A T Teriokhin; F Thomas
Journal:  Proc Biol Sci       Date:  2000-12-22       Impact factor: 5.349

2.  Dopamine receptor genetic polymorphisms and body composition in undernourished pastoralists: an exploration of nutrition indices among nomadic and recently settled Ariaal men of northern Kenya.

Authors:  Dan T A Eisenberg; Benjamin Campbell; Peter B Gray; Michael D Sorenson
Journal:  BMC Evol Biol       Date:  2008-06-10       Impact factor: 3.260

3.  High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.

Authors:  Mark Moran; Kenneth Blum; Jessica Valdez Ponce; Lisa Lott; Marjorie C Gondré-Lewis; Sampada Badgaiyan; Raymond Brewer; B William Downs; Philip Fynman; Alexander Weingarten; Jean Lud Cadet; David E Smith; David Baron; Panayotis K Thanos; Edward J Modestino; Rajendra D Badgaiyan; Igor Elman; Mark S Gold
Journal:  Mol Neurobiol       Date:  2021-03-08       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.